There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (INO), Arcturus Therapeutics Ltd (ARCT) and Armata Pharmaceuticals Inc (ARMP) with bullish sentiments.
Inovio Pharmaceuticals (INO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inovio Pharmaceuticals, with a price target of $13. The company’s shares closed yesterday at $3.02.
Selvaraju commented:
“Our 12-month price target is derived from a market value of the firm at $1.38B, which includes a discounted cash flow based asset value of $1.45B for 15% discount rate, 2% terminal growth rate, 80% probability of success, excluding $78.5M in debt and assuming 105M shares outstanding at the end of 1Q20. Risks include, but are not limited to: (1) failure of VGX-3100 in clinical trials; (2) failure of VGX-3100 to secure regulatory approval; (3) failure of VGX-3100 to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential dilution risk.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.3% and a 29.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inovio Pharmaceuticals with a $11 average price target.
See today’s analyst top recommended stocks >>
Arcturus Therapeutics Ltd (ARCT)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics Ltd, with a price target of $16. The company’s shares closed yesterday at $9.73, close to its 52-week high of $10.29.
Arce observed:
“We also expect the EMA to grant Orphan Drug status to ARCT-810, which is designed to provide similar benefits in the EU.”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.2% and a 36.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Arcturus Therapeutics Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $17, a 74.7% upside from current levels. In a report issued on June 20, Chardan Capital also reiterated a Buy rating on the stock with a $18 price target.
Armata Pharmaceuticals Inc (ARMP)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Armata Pharmaceuticals Inc, with a price target of $7. The company’s shares closed yesterday at $3.52, close to its 52-week low of $2.15.
Pantginis wrote:
“Valuation and risks to price target achievement. We maintain our Buy and $7 price target. The sole contributor to our valuation, at this point is AB-SA01, with a projected 15% chance of success with $415 million in peak sales off of a 2024 launch. Overall, we believe that our projected chance of success could be considered conservative based on the efficacy and safety profile, to date, in very sick patients, and continues to highlight the valuation disconnect, in our belief. We do not include projections for the P. aeruginosa program, and would look to reevaluate based on visibility on the path forward.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.5% and a 34.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Armata Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $8, which is a 127.3% upside from current levels. In a report issued on June 19, Ladenburg Thalmann & Co. also initiated coverage with a Buy rating on the stock with a $9 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
